Can BMS parlay its surprise 'win and a miss' in first-line lung cancer into a net gain? - FiercePharma

Can BMS parlay its surprise 'win and a miss' in first-line lung cancer into a net gain?  FiercePharma

If you thought you knew what was coming in Bristol-Myers Squibb's CheckMate-227 trial, forget it. The company's star immunotherapy Opdivo won one segment ...



Comments

Popular posts from this blog

Lymph node metastasis in cancer progression: molecular mechanisms, clinical significance and therapeutic ...

Stage 4 Lung Cancer Life Expectancy

A Review of the Etiology and Epidemiology of Bladder Cancer: All ...